Please assess the completion status of the following clinical trial:

Trial Title: 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Dyslipidemic participants with Chronic Kidney Disease Stage 3~* For entry into the Treatment Phase (Visit 3), the participant satisfied the following laboratory criteria (measured at the Screening Visit\[s\]):~  * Estimated glomerular filtration rate between 30 and 59 mL/min/1.73 m2 (Chronic Kidney Disease Stage 3) by simplified 4 variable Modification of Diet in Renal Disease formula (this includes a 10 percent variation in the upper limit of estimated glomerular filtration rate that was allowed for the enrollment of participants to account for variability in the creatinine assay).~ * Fasting lipid results following greater than or equal to 12-hour fasting period:~* Triglycerides level greater than or equal to 150 mg/dL,~* High-density lipoprotein cholesterol less than 40 mg/dL for males and less than 50 mg/dL for females, and~* Low-density lipoprotein cholesterol greater than or equal to 130 mg/dL Exclusion Criteria~* Participants with certain chronic or unstable medical conditions.~* Participants with unstable dose of medications or receiving coumarin anticoagulants, systemic cyclosporine, or certain other medications.~* Pregnant or lactating women, or women intending to become pregnant.~* Participants with diabetes mellitus that is poorly controlled.~* Participants of Asian ancestry (having Filipino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian origin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-335 plus rosuvastatin (Type: EXPERIMENTAL): ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
- Rosuvastatin (Type: ACTIVE_COMPARATOR): Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).